TITLE

Topical Methyl Aminolevulinate: A Viewpoint by Lesley E. Rhodes

AUTHOR(S)
Rhodes, Lesley E.
PUB. DATE
February 2004
SOURCE
American Journal of Clinical Dermatology;2004, Vol. 5 Issue 2, p138
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Offers information on methyl aminolevulinate, a topical prodrug used in the treatment of cutaneous lesions. Indications for and administration of the prodrug; Findings of clinical trials on the application of the prodrug; Advantages of methyl aminolevulinate photodynamic therapy.
ACCESSION #
13030321

 

Related Articles

  • KemPharm, Inc. Announces Initiation of Phase 1 Trial of KP201 for Pain.  // Biomedical Market Newsletter;3/14/2011, p469 

    The article announces the start of the Phase 1 clinical trial in healthy volunteers with KP201 prodrug for pain by North Liberty, Iowa-based KemPharm Inc. The drug is considered as the most advanced opioid-based lead candidate in the company's emerging pipeline. The clinical trial is intended to...

  • Gabapentin and nortriptyline combined was better than either drug alone for relief of neuropathic pain. Hughes, James // ACP Journal Club;3/16/2010, Vol. 152 Issue 3, p5 

    The article focuses on a medical research related to effectiveness of combined gabapentin and nortriptyline in comparison to alone drug for neuropathic pain. In a clinical trial around 56 patients with neuropathy is being observed and treated with combined drugs. It concluded that gabapentin and...

  • Withholding intravenous drugs did not improve survival to hospital discharge in out-of-hospital cardiac arrest. Stiell, Ian G. // ACP Journal Club;3/16/2010, Vol. 152 Issue 3, p7 

    The article offers information on a medical research related to intravenous drugs. It explores the effectiveness of withholding intravenous (IV) drugs in improvement of patient's health with out-of-hospital cardiac arrest. It concludes in a clinical trial that withholding intravenous drugs did...

  • A tutorial on pilot studies: the what, why and how. Thabane, Lehana; Jinhui Ma; Rong Chu; Ji Cheng; Ismaila, Afisi; Rios, Lorena P; Robson, Reid; Thabane, Marroon; Giangregorio, Lora; Goldsmith, Charles H // BMC Medical Research Methodology;2010, Vol. 10, p1 

    Pilot studies for phase III trials - which are comparative randomized trials designed to provide preliminary evidence on the clinical efficacy of a drug or intervention - are routinely performed in many clinical areas. Also commonly know as "feasibility" or "vanguard" studies, they are designed...

  • Promising Alzheimer's Drug Fails.  // MondayMorning;3/8/2010, Vol. 18 Issue 9, p3 

    The article reports that the drug, dimebon, for treating Alzheimer's disease, failed in the initial stage of its clinical trial. It informs that dimebon showed no effect after six months in treating Alzheimer's disease. Earlier trials were successful and dimebon worked really good and showed...

  • Double-Blind Active-Control Trials: Beware the Comparator You Keep. DiNubile, Mark J. // Clinical Infectious Diseases;10/15/2008, Vol. 47 Issue 8, p1064 

    The indirect impact of the known comparator drug in double-blind comparative clinical trials of novel agents is under appreciated, despite its potentially pernicious effects. This hypothesis-generating analysis illustrates potential spillover effects of a comparator (amphotericin) in the...

  • Operation Adaptive. Blake-Michaels, Molly // Applied Clinical Trials;Oct2009, Vol. 18 Issue 10, p52 

    The article reports on how the use of adaptive design could improve the overall effectiveness of a clinical trial. It notes that overall timeline may be compressed by using adaptive trials because of the higher information value and it can lower the development cost because it avoids additional...

  • Compromising the Medical Literature: The Hidden Influence of Industry-Biased Articles. FUGH-BERMAN, ADRIANE; SIWEK, JAY // American Family Physician;9/1/2011, Vol. 84 Issue 5, p489 

    This article comments on the influence of industry-biased articles published in medical journals in the U.S. It warns readers about clinical studies written for marketing rather than scientific purposes. It cautions readers about the efficacy and safety of drugs studied. In addition, the article...

  • Surrogate End Points and FDA Approval. Psaty, Bruce M.; Lumley, Thomas // JAMA: Journal of the American Medical Association;3/26/2008, Vol. 299 Issue 12, p1474 

    The authors reflect on the U.S. Food and Drug Administration's use of surrogate end points in evaluating the safety and effectiveness of drugs. They suggest that the advantage of using surrogate end points is the ability to evaluate drugs more effectively and in smaller clinical trials. They...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics